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Tissue inhibitor of metalloproteinases 1 (TIMP-1) is a matrix metal-
loproteinase (MMP)-independent regulator of growth and apopto-
sis in various cell types. The receptors and signaling pathways that
are involved in the growth factor activities of TIMP-1, however,
remain controversial. RNA interference of TIMP-1 has revealed that
endogenous TIMP-1 suppresses the proliferation, metabolic activ-
ity, and osteogenic differentiation capacity of humanmesenchymal
stem cells (hMSCs). The knockdown of TIMP-1 in hMSCs activated
the Wnt/β-catenin signaling pathway as indicated by the increased
stability and nuclear localization of β-catenin in TIMP-1–deficient
hMSCs. Moreover, TIMP-1 knockdown cells exhibited enhanced
β-catenin transcriptional activity, determined by Wnt/β-catenin tar-
get gene expression analysis and a luciferase-based β-catenin–
activated reporter assay. An analysis of a mutant form of TIMP-1
that cannot inhibit MMP indicated that the effect of TIMP-1 on
β-catenin signaling is MMP independent. Furthermore, the binding
of CD63 to TIMP-1 on the surface of hMSCs is essential for the
TIMP-1–mediated effects on Wnt/β-catenin signaling. An array
analysis of microRNAs (miRNAs) and transfection studies with spe-
cific miRNA inhibitors and mimics showed that let-7f miRNA is cru-
cial for the regulation of β-catenin activity and osteogenic differ-
entiation by TIMP-1. Let-7f was up-regulated in TIMP-1–depleted
hMSCs and demonstrably reduced axin 2, an antagonist of β-cat-
enin stability. Our results demonstrate that TIMP-1 is a direct reg-
ulator of hMSC functions and reveal a regulatory network in which
let-7f modulates Wnt/β-catenin activity.
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Tissue inhibitor of metalloproteinases 1 (TIMP-1) is a glyco-protein with a relative molecular weight of 28,500 that is
ubiquitously expressed in numerous human cells and tissues.
TIMP-1 belongs to a group of four endogenous inhibitors
(TIMP-1–TIMP-4) that control the activity of matrix metal-
loproteinases (MMP) and other metalloproteinases (1). In this
respect, TIMP-1 is an important regulator of extracellular matrix
turnover. TIMP-1 was discovered as a humoral protein that pro-
moted the proliferation of human erythroid progenitor cells (2).
Since then, TIMP-1 has been shown to exhibit multiple activities in
the regulation of various biological processes such as cell growth,
apoptosis, and differentiation that are independent of its metallo-
proteinase inhibitory activity (3). In this context, CD63, a member
of the tetraspanin family, has been identified as a binding protein
of TIMP-1 on the cell surface (4). However, little is known about
the downstream mechanisms of TIMP-1–mediated cell signaling.
Previously, we reported the constitutively high expression of
TIMP-1 in human mesenchymal stem cells (hMSCs) (5). This
observation prompted us to hypothesize that autocrine TIMP-1
may influence basic stem cell functions in these cells. Bone
marrow hMSCs are multipotent progenitor cells that are capable
of differentiating into osteocytes, chondrocytes, adipocytes, and
various nonmesodermal cell types, including neural cells (6–8).
These features make hMSCs valuable candidates for cell-based
therapies to regenerate tissues under various pathological con-
ditions, such as skeletal trauma, bone loss, cardiac disorders, and
neurodegenerative diseases (9–11). More recent findings provide
evidence that hMSCs may also be used therapeutically to mod-
ulate immune response in patients with tissue injury, trans-
plantation, and autoimmune disease because of their ability to
release diverse cytokines and chemokines (12).
The canonical Wnt/β-catenin pathway appears to play impor-
tant roles in multiple physiological and pathological processes
in hMSCs (13). In the absence of Wnt ligands, cytoplasmatic
β-catenin is constantly degraded through the activity of the axin
complex (14). Activation of the Wnt/β-catenin pathway is char-
acterized by the binding ofWnt ligands to specific receptors, which
enables the stabilization of cytoplasmatic β-catenin. In the absence
of the axin degradation complex, β-catenin is translocated into the
nucleus where it interacts with lymphoid-enhancer–binding fac-
tor-1/T-cell factor-1 (LEF/TCF) transcription factors, resulting in
the transcription of target genes such as cyclin D1 andmembrane-
type 1 matrix metalloproteinase (MT1-MMP) (14–16).
In recent years, noncoding RNA molecules known as micro-
RNAs (miRNAs) have increasingly gained attention because of
their important roles as posttranscriptional gene regulators in
numerous biological processes such as development, stem cell
regulation, and human disease (17, 18). miRNAs are mostly
transcribed from intragenic or intergenic regions and undergo
further processing by Drosha and other downstream ribonu-
cleases before being converted into mature 18- to 25-nt miRNA
transcripts that are capable of gene silencing. Several studies
have demonstrated that specific miRNAs or miRNA expression
profiles are associated with the intrinsic stem cell properties of
self-renewal and pluripotency (19, 20). Less work, however, has
focused on the roles of miRNAs in known regulatory networks
that control cell fate and differentiation in response to endoge-
nous and exogenous stimuli.
In the present study, we provide evidence that endogenous
TIMP-1 acts as a suppressor of hMSC growth and osteogenic dif-
ferentiation through negative modulation of Wnt/β-catenin sig-
naling activity. This effect requires the interaction of TIMP-1 and
CD63 on the cell surface and is independent of MMP-inhibitory
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activity. Furthermore, we found that the underlying regulatory
network involved the miRNA let-7f as a key factor targeting the
translation of axin 2, which promotes β-catenin degradation.
Results
Endogenous TIMP-1 Attenuates Growth and Osteogenic Differentiation.
To investigate whether endogenously expressed TIMP-1 influ-
ences the proliferation and metabolic activity of hMSCs, we
analyzed the effect of decreasing TIMP-1 biosynthesis in these
cells, using siRNA-mediated knockdown (Fig. S1A). Using the
CyQuant cell proliferation assay, we showed that hMSCs trans-
fected with siRNA directed against TIMP-1 demonstrated a sig-
nificant increase in proliferative activity after 3 d of incubation and
a less marked increase in proliferative activity after 7 d of in-
cubation than cells treated with a control siRNA (Fig. 1A). The
results of aWST-1 proliferation assay demonstrated that TIMP-1–
deficient hMSCs had robust augmentation of mitochondrial de-
hydrogenase activity after 3 and 7 d of cultivation relative to the
control cells (Fig. 1B).
We then determined whether endogenous TIMP-1 influenced
hMSC differentiation into the osteogenic lineage. hMSCs trans-
fected with either siRNA targeting TIMP-1 or control siRNA were
grown to subconfluency and subsequently cultivated in osteogenic
differentiation media. After 14 d, microscopic analysis of the
alizarin red-stained monolayers revealed higher levels of miner-
alization in TIMP-1 knockdown hMSCs than in control cells (Fig.
1C). To further evaluate the effect of TIMP-1 down-regulation on
the osteogenic differentiation of hMSCs, the expression levels of
specific differentiation markers (alkaline phosphatase, osteocalcin,
and decorin) were assayed in cells grown under osteogenic con-
ditions for 14 d. TIMP-1–deficient hMSCs demonstrated a 15-fold
increase in alkaline phosphatase, a 7-fold increase in osteocalcin,
and a 2-fold increase in the levels of decorin mRNA relative to
control cells (Fig. 1D).
Together, these findings suggest that endogenous TIMP-1 acts
as a negative regulator of hMSC growth and osteogenic dif-
ferentiation.
TIMP-1 Reduces Wnt/β-Catenin Signaling Activity Independently of Its
MMP Activity. To investigate the influence of endogenous TIMP-1
on hMSC gene expression in detail, we conducted microarray
analysis using the Human Signal Transduction PathwayFinder
Gene Array (SABiosciences), which evaluates transcriptional
changes in 96 different genes associated with 18 signal trans-
duction pathways. Microarray analysis was carried out in hMSCs
3 d after transfection with TIMP-1 siRNA or control siRNA.
Down-regulation of TIMP-1 enhanced the mRNA expression of
16 genes in hMSCs, whereas only 1 gene (bone morphogenetic
protein 4) exhibited reduced mRNA levels. The majority of genes
up-regulated in the TIMP-1–deficient hMSCs are implicated in
the Wnt signaling pathway, i.e., WISP1 (WNT-inducible signaling
pathway protein 1), WISP2, WISP3, TCF7 (transcription factor 7,
T-cell specific), MYC (v-myc myelocytomatosis viral oncogene ho-
molog), JUN (jun oncogene), and BIRC5 (baculoviral IAP repeat-
containing 5, also termed survivin) (Table S1).
The activation of the Wnt/β-catenin pathway is characterized
by (i) the stabilization of cytoplasmatic β-catenin, (ii) the translo-
cationofβ-catenin into thenucleus, (iii) the interactionof β-catenin
with TCT/LEF transcription factors, and (iv) the increased expres-
sion of β-catenin target genes. Therefore, we investigated each of
these features experimentally. Western blot analysis revealed that
β-catenin protein levels were elevated in the hMSCs on days 3 and
7 after TIMP-1 knockdown compared with control cells (Fig. 2A).
Immunocytochemical analysis demonstrated that hMSCs trans-
fected with siRNA against TIMP-1 demonstrated strong nuclear
staining of β-catenin and that this staining was weaker in cells
transfected with control siRNA (Fig. 2B).
Furthermore, we used a Gaussia luciferase-based reporter
system to investigate the activation of β-catenin target promoters.
The β-catenin–activated reporter (BAR) system can be used to
specifically monitor β-catenin activity on TCF/LEF-dependent
gene transcription (e.g., Gaussia luciferase). hMSCs transfected
with the BAR system (BAR-hMSCs) were treated with siRNA
targeting TIMP-1 or control siRNA and cultivated for up to 7 d
in the presence of Wnt3a to stimulate β-catenin activity. These
studies revealed that β-catenin reporter activity was significantly
Fig. 1. TIMP-1 knockdown promotes proliferation, metabolic activity, and osteogenic differentiation in hMSCs. (A) Quantification of hMSC cells at 3 and 7 d
after transfection with TIMP-1 siRNA (KD) or control siRNA (NC, set as 100%) using the CyQuant cell proliferation assay. (B) Analysis of mitochondrial de-
hydrogenase activity in the hMSCs at 3 and 7 d after transfection with TIMP-1 siRNA (KD) or control siRNA (NC) using the WST-1 assay. (C, D) hMSCs
transfected with control siRNA (NC) or siRNA targeting TIMP-1 (KD) were incubated in osteogenic differentiation medium. (C) Representative microscopic
images of cellular monolayer mineralization after alizarin red staining on day 14 of osteogenic differentiation (magnification 4×). (D) Relative mRNA levels of
the differentiation markers alkaline phosphatase, osteocalcin, and decorin in the hMSCs on day 14 of osteogenic differentiation. Values were normalized to
GAPDH mRNA. All results are given as mean values ± SD of triplicate measurements (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001.
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enhanced in hMSCs with impaired TIMP-1 biosynthesis relative
to control cells over the 7-d period of measurement (Fig. 2C).
To confirm the inhibitory effect of TIMP-1 on β-catenin–de-
pendent signaling in hMSCs, we performed qRT-PCR analysis of
the Wnt/β-catenin target genes cyclin D1 and MT1-MMP, which
contain TCF/LEF-binding sites in their promoter regions (15, 16).
hMSCs transfected with siRNA targeting TIMP-1 or control
siRNA were cultured for 7 d in the presence or absence of Wnt3a
and recombinant TIMP-1. Wnt3a clearly up-regulated the basal
transcription of cyclin D1 and, to a lesser extent, MT1-MMP.
TIMP-1–deficient hMSCs demonstrated a further increase in
cyclin D1 and MT1-MMP expression, which was abolished upon
the addition of recombinant TIMP-1 (Fig. 2D). Taken together,
these data indicate that TIMP-1 is a negative regulator of Wnt/
β-catenin activity in hMSCs.
We conducted several experiments with a recombinant mutant
form of TIMP-1 to clarify whether the effect of TIMP-1 on Wnt/
β-catenin activity is dependent or independent of its MMP in-
hibitory activity. The mutant TIMP-1, referred to as Val-Val-
TIMP-1, was engineered to contain two valine residues appended
to the amino-terminal cysteine-1 of the normal wild-type (WT)
TIMP-1. This modification results in a loss of inhibitory activity
(Fig. S2) by disrupting the cysteine-1 interaction with the active
zinc atom in the catalytic domain of MMPs (1, 21). BAR-hMSCs
were cotransfected with siRNA against TIMP-1 or control siRNA
and cultivated for 24 h in the absence or presence of Wnt3a, Val-
Val-TIMP-1, and WT-TIMP-1. Luminometric quantification of
reporter activity (Gaussia luciferase) revealed that the non-MMP–
inhibiting Val-Val-TIMP-1 substantially inhibited both basal and
Wnt3a-stimulated β-catenin signaling, similar to WT-TIMP-1.
This effect was more pronounced in TIMP-1–deficient hMSCs
than in control cells (Fig. 2E). These findings suggest that
TIMP-1–mediated suppression of Wnt/β-catenin activity in
hMSCs does not rely on the MMP inhibitory activity of TIMP-1.
CD63 Transduces TIMP-1–Mediated Effects on Wnt/β-Catenin Signaling.
Cells were subjected to confocal microscopic analysis to determine
whether CD63 binds to TIMP-1 on the surface of hMSCs. Im-
munofluorescence staining of nonpermeabilized hMSCs demon-
strated the strong expression of both proteins on the plasma
membrane. CD63 and TIMP-1 exhibited punctate costaining that
was distributed unevenly on the cellular periphery, consistent with
cell surface colocalization; this pattern was also documented by
fluorescence intensity profiling analysis (Fig. 3A), and these find-
ings were validated by coimmunoprecipitation analysis. Endoge-
nous CD63 complexed with TIMP-1 was immunoprecipitated
from hMSC lysates using an anti-CD63 antibody (Fig. 3B). After
knockdown of CD63 in these cells (Fig. S1B), the amount of
TIMP-1 that coprecipitated with the anti-CD63 antibody de-
creased (Fig. 3B). Moreover, Western blot and qRT-PCR analyses
demonstrated that the CD63-deficient hMSCs had reduced levels
of cell-associated TIMP-1 and elevated levels of soluble TIMP-1
in culture supernatants, but that there was no change in TIMP-1
mRNA expression (Fig. 3C). These results suggest that CD63 acts
as a binding partner for TIMP-1 on the surface of hMSCs.
Next, we treated BAR-transfected hMSCs with siRNA against
CD63 and observed a significant increase in TCF/LEF-dependent
reporter activity in both the absence and presence of Wnt3a rel-
ative to cells that had been treated with control siRNA (Fig. 3D).
Upon addition of recombinant TIMP-1 to CD63 knockdown
hMSCs, the increase in β-catenin activity was less pronounced and
Fig. 2. TIMP-1 reduces Wnt/β-catenin activity in a MMP-independent manner. (A) Western blot analysis of β-catenin and TIMP-1 in protein extracts obtained
from hMSCs transfected with siRNA targeting TIMP-1 (KD) or control siRNA (NC) on days 3 and 7 after transfection. For densitometric quantification, the
amount of β-catenin present in cells transfected with control siRNA was set to 100% at each time point. Cellular β-actin was used as a loading control (n = 3).
(B) Images of the immunocytochemical staining of β-catenin in hMSCs transfected with siRNA against TIMP-1 (KD) or control siRNA (NC) 3 d after transfection
(n = 3) at magnification 10×. (C) TIMP-1 knockdown (KD) and control (NC) hMSCs were transiently transfected with the β-catenin–activated reporter (BAR) and
cultivated for up to 7 d in the presence of Wnt3a (150 ng/mL) to stimulate Wnt/β-catenin activity. The activity of secreted Gaussia luciferase, which was
transcribed due to β-catenin–dependent TCF/LEF signaling in the cells, was quantified in the conditioned medium at the indicated time points. (D) hMSCs
transfected with TIMP-1 siRNA or control siRNA were cultured in the presence or absence of Wnt3a (150 ng/mL) and/or recombinant TIMP-1 (20 nM). After 7 d
of incubation, the transcription levels of the Wnt/β-catenin target genes cyclin D1 and MT1-MMP were examined using qRT-PCR. The results are given as the
percentage of change in mRNA expression relative to that in unstimulated control cells transfected with control siRNA. (E) The effects of wild-type TIMP-1
(WT-TIMP-1) and a non-MMP–inhibitory mutant form of TIMP-1 (V-V-TIMP-1) (each 20 nM) on β-catenin reporter activity in BAR-hMSCs without (NC) and with
TIMP-1 knockdown (KD) in the absence (basal) and presence of Wnt3a (150 ng/mL) after 24 h of incubation. The data shown in C–E represent the mean ± SD
of triplicate measurements (n = 3). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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almost absent in cells incubated without and with Wnt3a, re-
spectively (Fig. 3D). Furthermore, theWnt/β-catenin target genes
cyclin D1 and MT1-MMP were up-regulated in CD63-deficient
hMSCs (Fig. 3E).
When taken together, these findings demonstrate that CD63
is a receptor for endogenous TIMP-1 and implicate CD63 in
the regulation of the Wnt/β-catenin signaling activity of hMSCs
by TIMP-1.
The miRNA let-7f Regulates the TIMP-1-Mediated Inhibition of Wnt/
β-Catenin Signaling. BAR-hMSCs were subjected to RNAi against
Drosha (Fig. S1C) to determine whether TIMP-1–mediated
Fig. 3. TIMP-1 binding to the cell surface molecule CD63
affects Wnt/β-catenin signaling. (A) Confocal microscopic
analysis of hMSCs costained with anti-TIMP-1/Alexa 543–
conjugated secondary antibody (red staining), anti-CD63/
Alexa 488–conjugated secondary antibody (green staining),
and Hoechst 33342 (blue staining, for DNA labeling in cell
nuclei). The merged image shows the overlay (yellow
staining) of the two channels demonstrating TIMP-1 coloc-
alization with CD63. The area marked by a square is shown
in higher magnification to display the representative sec-
tion (white arrow) used for fluorescence intensity profiling
analysis. Intensity peaks representing the red (TIMP-1) and
green (CD63) emission wavelengths indicate areas of
colocalization (black arrows). (B) Anti-CD63 immunopreci-
pitates (IPs) obtained from hMSC lysates 3 d after trans-
fection using a specific siRNA against CD63 (KD) or control
siRNA (NC) were subjected to Western blotting, using anti-
CD63 and anti-TIMP-1 antibodies. The detection of β-cat-
enin in the cell lysates before immunoprecipitation served
as a control. (n = 3). (C) hMSCs were transfected with siRNA
against CD63 (KD) or control siRNA (NC). Equal amounts of
protein were taken from the cell lysates and conditioned
media (CM), and the presence of TIMP-1 was evaluated by
Western blotting after 3 d of incubation. For densitometric
quantification, the amounts of TIMP-1 present in the con-
trol cell lysate and the CM were set as 100%, respectively.
TIMP-1 mRNA levels were determined using qRT-PCR after
24 h of incubation (n = 3). (D) BAR-hMSCs were transfected
with siRNA targeting CD63 (KD) or a control siRNA (NC) and
cultured for 3 d in the absence (basal) or presence of Wnt3a
(150 ng/mL) and/or recombinant TIMP-1 (20 nM) (+T).
β-Catenin reporter activity was quantified by measuring
secreted Gaussia luciferase in the conditioned medium
(CM). (E) hMSCs transfected with siRNA against CD63 (KD)
or control siRNA (NC) were incubated for 3 d in the presence
of Wnt3a (150 ng/mL), and the transcription levels of the
Wnt/β-catenin target genes cyclin D1 and MT1-MMP were
analyzed using qRT-PCR. The data shown in D and E rep-
resent the mean ± SD (n = 3). **P < 0.01; ***P < 0.001.
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modulation of the Wnt/β-catenin activity in hMSCs is associated
with changes in miRNA expression. Drosha is a key regulatory
enzyme in miRNA biogenesis. At 3 d after transfection, Drosha-
deficient hMSCs demonstrated a significant decrease in sus-
ceptibility to the TIMP-1 knockdown-mediated up-regulation of
β-catenin activity (Fig. 4A).
To identify specific miRNAs involved in the regulation of
hMSCs by TIMP-1, we silenced TIMP-1 expression and analyzed
the subsequent transcriptional changes in 88 abundantly expressed
and well-characterized miRNA sequences, using the Human
miFinder RT2 miRNA PCR Array (SABiosciences). Microarray
analysis was carried out in hMSCs after 3 d of incubation following
transfection with an siRNA targeting TIMP-1 or a control siRNA.
The down-regulation of TIMP-1 in hMSCs modulated the tran-
scription of numerous miRNAs, with the greatest increase ob-
served in let-7f (Fig. 4B and Table S2). Quantification by qRT-PCR
demonstrated an 18-fold augmentation of let-7f in TIMP-1–de-
pleted hMSCs (Fig. 4C). Moreover, transcription of let-7f was in-
creased 2- to 3-fold upon knockdown of CD63 in the cells (Fig. 4C).
Next, we studied the role of let-7f in more detail by transfecting
hMSCs with let-7f miRNA (chemically synthesized, double-
stranded RNA that mimics mature endogenous let-7f) and a let-
7f miRNA inhibitor (chemically modified, single-stranded RNA
designed to specifically bind and inhibit endogenous let-7f). The
addition of the let-7f mimic to hMSCs slightly augmented β-cat-
enin activity, whereas the inhibition of let-7f efficiently blocked
Fig. 4. The miRNA let-7f is implicated in the TIMP-1–mediated inhibition of β-catenin activity and osteogenic differentiation. (A) BAR-hMSCs were trans-
fected with control siRNA (NC), siRNA targeting TIMP-1 (KD), and/or siRNA targeting Drosha (KD). After 3 d of culture, β-catenin reporter activity was de-
termined by luminometric analysis of Gaussia luciferase in the culture supernatants. (B) hMSCs were transfected with control siRNA (NC) or siRNA targeting
TIMP-1 (KD) and incubated for 3 d. RNA was collected and subjected to miRNA analysis, using PCR array technology. The results are shown in a diagram with
the crossing point (Ct) values in TIMP-1 knockdown cells plotted against the respective Cts in control cells and fitted well to a straight line, revealing that let-7f
was the most up-regulated miRNA tested. (C) Quantitation of let-7f transcription in control cells (NC, set as 1) and hMSCs deficient (KD) in TIMP-1 and CD63
using qRT-PCR analysis. The values shown were normalized to GAPDH mRNA. (D) BAR-hMSCs were transfected with control siRNA (NC), siRNA against TIMP-1
(KD), a let-7f mimic (MI), and/or a let-7f inhibitor (IN). After 24 h of incubation, β-catenin reporter activity was quantified by luminometric measurement of
secreted Gaussia luciferase in the conditioned medium (the control was set as 100%). (E) hMSCs were cotransfected with a Renilla luciferase reporter construct
bearing the axin 2 3′-UTR and a let-7f mimic (10–40 nM) or control miRNA (40 nM). After 24 h, axin 2 reporter activity was quantified by luminometric
measurement of Renilla luciferase in the cell extracts. (F) hMSCs were transfected with control siRNA (NC), siRNA against TIMP-1 (KD), a let-7f mimic (MI), and/
or a let-7f inhibitor (IN) and cultivated in the presence of Wnt3a (150 ng/mL) to stimulate Wnt/β-catenin signaling. After 24 h, axin 2 protein expression was
analyzed using Western blotting, and axin 2 mRNA expression was analyzed using qRT-PCR. β-Actin served as a loading control. For densitometric quanti-
fication, the amount of axin 2 protein present in the control cells (NC) was set as 100%. The qRT-PCR values shown were normalized to the GAPDH mRNA
levels. (G–I) hMSCs transfected with control siRNA (NC), siRNA targeting TIMP-1 (KD), a let-7f mimic (MI), and/or a let-7f inhibitor (IN) were incubated for 14 d
in osteogenic differentiation medium. (G) Representative images of cellular monolayer mineralization with alizarin red staining. (H) The relative absorbance
of the alizarin red stain extracts (the NC was set as 100%). (I) Relative mRNA levels of the osteogenic markers alkaline phosphatase and osteocalcin were
determined using qRT-PCR (the NC was set as 1). The values are normalized to the GAPDH mRNA levels. Data shown in A, C–F, H, and I are given as mean
values ± SD of triplicate measurements (n = 3). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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the up-regulation of β-catenin signaling in TIMP-1–deficient
hMSCs (Fig. 4D). These data indicate that let-7f participates in
the TIMP-1–mediated regulation of β-catenin activity in hMSCs.
We then searched for potential let-7f targets, i.e., negative
regulators of the Wnt/β-catenin signaling pathway that are com-
plementary to (and therefore may be repressed by) let-7f. Using
an in silico prediction algorithm, we discovered that let-7f may
target axin 2 (axis inhibition protein 2), a cytoplasmatic protein
that plays a key role in β-catenin degradation (22). The targeting
was verified experimentally using a luciferase reporter assay and
the 3′-untranslated region (UTR) of axin 2. When hMSCs were
cotransfected with the reporter construct and increasing amounts
of the let-7f mimic, the axin 2-specific luciferase activity was re-
duced in both unstimulated and Wnt3a-stimulated cells in a dose-
dependent manner (Fig. 4E). Moreover, Western blot analysis
demonstrated a clear decrease in the biosynthesis of axin 2 pro-
tein in the presence of the let-7f mimic and a rescue of axin 2
protein levels in TIMP-1 knockdown hMSCs upon inhibition of
let-7f (Fig. 4F). Axin 2 mRNA expression was not affected by
either a let-7f mimic or a let-7f inhibitor (Fig. 4F), indicating that
let-7f regulates axin 2 at the posttranscriptional level. Taken to-
gether, these results provide evidence that let-7f promotes
β-catenin activity in hMSCs by repressing the translation of axin 2.
Finally, we examined whether let-7f is involved in the regulation
of osteogenic differentiation. Transfection with a let-7f mimic
further increased cellular mineralization and osteogenic marker
expression in hMSCs under osteogenic conditions. In contrast, the
inhibition of let-7f activity by the transfection of a specific inhibitor
abolished the increase of mineralization (Fig. 4 G and H) and
osteogenic marker expression (Fig. 4I), as observed in TIMP-1–
deficient cells grown in osteogenic media. These data indicate that
let-7f expression in hMSCs promotes osteogenic differentiation.
Discussion
Our current study describes a mechanism by which TIMP-1 reg-
ulates essential stem cell functions. The inhibition of TIMP-1
expression in hMSCs significantly promoted cell growth and dif-
ferentiation into adult cells of the osteogenic lineage, indicating
that TIMP-1 is an endogenous attenuator of these processes.
Previous reports have shown that TIMP-1 inhibits epithelial cell
proliferation and osteoblastic differentiation (23, 24) but stim-
ulates differentiation in hematopoietic progenitor cells, B cells,
and Burkitt lymphoma cells (25–27). However, none of these
studies has provided information regarding the underlying mo-
lecular mechanisms. Because TIMP-1 is secreted from hMSCs at
relatively high levels in the absence of its major target protease
MMP-9 (5), we hypothesized that TIMP-1 may also mediate
signaling that affects gene expression and inhibits the growth and
differentiation of these cells.
Our studies revealed that knockdown of TIMP-1 production in
hMSCs up-regulates the stability, nuclear translocation, and
promoter activity of β-catenin, demonstrating that TIMP-1 is an
inhibitor of β-catenin–dependent signaling. The Wnt/β-catenin
signaling pathway is closely associated with the growth and de-
velopment of stem cells (13). In hMSCs, increased stability and/
or activity of β-catenin has been shown to promote osteogenic
differentiation, which may also occur independently of stimula-
tion with Wnt (28, 29). In the present study, both endogenous
TIMP-1 and exogenously added recombinant TIMP-1 acted as
negative regulators of β-catenin activity in hMSCs, thereby pre-
venting up-regulation of the β-catenin target genes cyclin D1 and
MT1-MMP. Consistent with our data, TIMP-1 down-regulates
cyclin D1 in human breast epithelial (MCF10A) cells (30).
We showed that TIMP-1 colocalizes with CD63 on the surface
of hMSCs, which appears to be one extracellular mechanism
by which TIMP-1 reassociates with the hMSC plasma membrane.
In addition to CD63, other molecular structures appear to act as
docking proteins for TIMP-1 on the plasmamembrane of hMSCs;
these structures will need to be identified by further studies.
Nevertheless, CD63 plays an important role in the TIMP-1–me-
diated interference of the Wnt/β-catenin pathway. Functional
depletion of CD63 in hMSCs significantly up-regulated Wnt/
β-catenin activity even though TIMP-1 was still expressed in these
cells. This result is consistent with previous reports demonstrating
that CD63 can regulate the activity of the phosphatidylinositol 3-
kinase, focal adhesion kinase, Src, and Akt signaling pathways, all
of which have been implicated in the anti-apoptotic activity of
TIMP-1 (31–33). Addition of an excess of TIMP-1 to CD63-de-
pleted hMSCs attenuated the increase ofWnt/β-catenin activity in
these cells, again indicating that CD63 is not the exclusive struc-
ture that interacts with TIMP-1 and thereby affects gene expres-
sion in these cells.
To further elucidate the intracellular molecular mechanism by
which TIMP-1 suppresses the stability and activity of β-catenin in
hMSCs, we focused on miRNAs, which have very recently been
shown to play important roles in the self-renewal and differenti-
ation of hMSCs (20). Functional disruption of the miRNA pro-
cessing machinery significantly inhibited the increase in β-catenin
activity in TIMP-1–depleted hMSCs, suggesting that precise levels
of mature miRNAs are critical for the TIMP-1–mediated modu-
lation of β-catenin. This finding is consistent with other recent
data demonstrating that various miRNAs can act as positive or
negative regulators of β-catenin transcriptional activity (34).
Among the miRNAs that were up-regulated after knockdown of
TIMP-1 biosynthesis in our hMSC experiments, let-7f exhibited
the most pronounced increase. This is especially interesting be-
cause the let-7 family of miRNAs is thought to represent “pro-
differentiation” factors with “antistemness” properties (35). For
example, mature let-7 miRNAs are undetectable in embryonic
stem cells but accumulate strongly after the onset of differentia-
tion in these cells (36). Moreover, other studies in hMSCs have
demonstrated that specific let-7 miRNAs are up-regulated during
osteogenic differentiation and presumably down-regulate factors
that inhibit osteogenesis (37, 38).
miRNAs can modulate β-catenin–dependent transcription in
several ways, including the direct inhibition of β-catenin mRNA or
the indirect inhibition of negative and positive regulators of
β-catenin activity (34). Axin 2 is a negative regulator of the Wnt/
β-catenin signaling pathway and was identified in silico and in vitro
as a let-7f target in hMSCs. Similar to its homolog axin 1, axin 2 is
thought to act as a scaffolding protein that organizes a multi-
protein complex that can degrade β-catenin (39). Indeed, axin 2
translation is abrogated in TIMP-1–depleted hMSCs, concomitant
with the increased β-catenin activity observed in these cells. Fur-
thermore, axin 2 protein levels were rescued upon let-7f inhibition,
confirming that axin 2 is a target of let-7f. Axin 2 down-regulation
by let-7f may explain the direct increase in β-catenin activity by let-
7f in hMSCs. Although additional miRNAs are clearly involved in
the control of osteogenic differentiation in hMSCs, our findings
indicate that let-7f is a key miRNA in this process.
In conclusion, we have demonstrated that TIMP-1 is a negative
regulator of the growth and osteogenic differentiation of hMSCs
and thus promotes a quiescent state in these cells. TIMP-1 binding
to CD63 on the surface of hMSCs results in the repression of
let-7f miRNA expression, thereby stabilizing the levels of axin 2
and subsequently promoting the degradation of β-catenin. Impor-
tantly, our results show that the functional depletion of TIMP-1
or an increase in let-7f accelerates osteogenic differentiation in
hMSCs. A deeper knowledge of this regulatory network may
improve the development of novel therapeutic approaches to
enhance bone formation during pathological bone loss.
Experimental Procedures
Cultivation, Osteogenic Differentiation, and Alizarin Red Staining of hMSCs.
hMSCs from bone marrow aspirates were purchased from Lonza as frozen
vials of passage-one cells. Each hMSC lot was tested by Lonza for purity using
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flow cytometry and for their ability to differentiate into osteogenic, chon-
drogenic, and adipogenic lineages. The cells were positive for CD105, CD166,
CD29, and CD44 and negative for CD14, CD34, and CD45.
hMSCswere cultured as described previously, using themesenchymal stem-
cell growth medium (MSCGM) BulletKit (Lonza) (8). For experiments under
serum-free conditions, hMSCs were washed with serum-free medium and in-
cubated in DMEM supplemented with 1% Nutridoma SP (Roche Applied Sci-
ence) in the presence or absence of 20 nM human recombinant TIMP-1
(Peprotech), thenull-inhibitionmutantVal-Val-TIMP-1, or its activeanalogWT
TIMP-1, both kindly provided by P. Nelson, Ludwig-Maximilians-University.
Osteogenic differentiation and alizarin red staining of hMSCs were per-
formed as previously described (40). Alizarin red stain incorporation was
quantified by extracting stained monolayers with a solution containing 50%
ethanol, 10% methanol, and 2% SDS. Aliquots of the extracted dye were
then transferred to 96-well plates and the absorbance at 405 nm was
measured using a plate reader (Tecan). All studies were carried out with
hMSCs from the fifth or sixth passage.
CyQuant Cell Proliferation Assay and WST-1 Assay for Cell Metabolic Activity.
Cell proliferationwas quantified using the CyQuant cell proliferation assay kit
(Invitrogen) as previously described (40). Briefly, nucleic acids present in cell
lysates were stained with fluorescent CyQuant GR dye before measurement
at 480 nm (excitation) and 530 nm (emission). For each experiment, a stan-
dard calibration curve was generated by plotting the measured fluorescence
values of the samples vs. the corresponding number of cells, which had been
determined before staining using a hematocytometer.
TheWST-1 assay (Roche Applied Science), which is based on the cleavage of
the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells,
was conducted according to the manufacturer’s protocol.
qRT-PCR Analysis of mRNA and miRNA Expression. RNA isolation, cDNA syn-
thesis, and PCR were performed as described in ref. 5. qRT-PCR was carried
out on a LightCycler (Roche Applied Science), using the LightCycler-FastStart
DNA Master SYBR Green I Kit (Roche Applied Science). For amplification of
specific human transcripts, the LightCycler Primer Sets for alkaline phos-
phate, osteocalcin, decorin, cyclin D1, MT1-MMP, axin 2, and the house-
keeping gene standard GAPDH were used following the manufacturer’s
instructions (Search LC).
The expression of select miRNAs was determined using the miScript PCR
System (Qiagen), which converts miRNA into cDNA, which was detected using
SYBR Green-based RT-PCR. The let-7f primer sequence is given in Table S3.
Transfection of hMSCs with siRNA, miRNA Mimics, and miRNA Inhibitors. RNA
interference (RNAi) technology was used to generate specific knockdowns of
TIMP-1, CD63, and Drosha expression in hMSCs. siRNA sense and antisense
oligonucleotides targeting human TIMP-1 mRNA were designed in our lab-
oratory according to the protocol of Reynolds et al. (41) and synthesized by
Qiagen. siRNA against CD63, Drosha, and a nonspecific siRNA with no target
in the human transcriptome (used as a negative control) were purchased
from Qiagen. For studies of miRNA function and gene regulation, miScript
miRNA mimics and miScript miRNA inhibitors of let-7f were used (Qiagen).
The sequences of all siRNAs, miRNA mimics, and miRNA inhibitors used are
listed in Table S3. hMSCs were transfected with miRNA mimics (20 nM) and
miRNA inhibitors (20 nM) according to a previously described method for
hMSC transfection with siRNA (5).
miRNA Target Prediction and Experimental Validation of Target Genes. We
used the computational target prediction algorithm miRanda to identify
mature gene transcripts that might be targeted by let-7f at their 3′-UTRs (42).
Axin 2 was then experimentally verified as a let-7f target gene in hMSCs
according to the protocol suggested by Huang et al. (43).
Reporter assays used a LightSwitch GoClone 3′-UTR Reporter Construct
(BioCat) based on the 3′-UTR sequence of axin 2, which was cloned down-
stream of the Renilla luciferase gene. hMSCs grown in microtiter plates were
cotransfected with the axin 2 reporter plasmid (100 ng) and either the let-7f
mimic (10–40 nM) or the control siRNA (40 nM) (Qiagen). After 24 h of in-
cubation, 100 μL of LightSwitch reagent (BioCat) was added to each well,
and luminescence was measured using a plate-reading luminometer (Tecan).
The effect of let-7f on axin 2was examined byWestern blot analysis of axin
2 protein levels in hMSC extracts 24 h after treatment with the let-7f mimic or
inhibitor. qRT-PCR analysis was performed to quantitate the level of axin 2
transcript in the hMSCs 1 d after incubation with the let-7f mimic or inhibitor.
Transcription-Based Reporter Assay of Wnt/β-Catenin Signaling. The activity of
the Wnt/β-catenin signaling pathway, which culminates in the TCF/LEF-
dependent regulation of target gene transcription, was monitored in the
hMSCs, using a reporter assay. This assay was based on the BAR, which
contains multimerized TCF/LEF DNA-binding sites, and the control reporter,
found-unresponsive BAR (fuBAR) (44). We modified the BAR/fuBAR by
cloning Gaussia luciferase as the reporter gene to allow the detection of the
reporter in the supernatant; after its transcription is activated by β-catenin,
Gaussia luciferase is secreted from the cells, so the cells do not have to be
destroyed to assay its transcription.
hMSCs were transfected with the BAR (or fuBAR, which harbors mutant
TCF-binding sites) Gaussia luciferase reporter plasmid and cultivated in the
presence of geneticin (100 μg/mL) to eliminate nontransfected cells. Then,
the BAR/fuBAR-hMSCs were used for the stimulation and/or knockdown
experiments. Conditioned medium was collected after the indicated time
intervals and analyzed for the presence of reporter protein, using the
Gaussia luciferase assay kit (New England Biolabs) according to the manu-
facturer’s protocol. The light intensity was determined using a plate-reading
luminometer (Tecan). No Gaussia luciferase activity was detected in condi-
tioned media from hMSCs transfected with the fuBAR system in any ex-
periment performed in this study.
Western Blot and Coimmunoprecipitation Analyses. Protein extraction from
the hMSCs, SDS/polyacrylamide gel electrophoresis, and Western blotting
were performed as described in ref. 5. The blotted membranes were in-
cubated overnight with monoclonal antibodies against β-actin (1:2,000)
and TIMP-1 (1:500) (both from Abcam), β-catenin (1:500) (Santa Cruz
Biotechnology), CD63 (1:1,000) (Millipore), or axin 2 (1:1,000) (Cell Sig-
naling Technology) diluted in Tris-buffered saline containing 0.1%
Tween-20 (TBS-Tween buffer) containing 5% BSA. The membranes were
washed in TBS-Tween buffer and then incubated with peroxidase-conju-
gated anti-rabbit IgG (Cell Signaling Technology) at a dilution of 1:8,000
in TBS-Tween for 30 min. Bound antibodies were detected using the
enhanced chemiluminescence system (GE Healthcare Life Sciences).
Recombinant protein standards (Invitrogen) were used for molecular
mass determination.
Coimmunoprecipitation was performed to investigate protein inter-
actions. Total hMSC lysates were prepared in lysis buffer as described in ref. 5.
Aliquots (10 μg of protein) were incubated overnight at 4 °C with anti-CD63
(2 μg) (Millipore) or control IgG in TBS-Tween. The immunocomplexes were
collected on protein A agarose beads (Invitrogen), following the manu-
facturer’s instructions. Bound proteins/complexes were then eluted and
subjected to Western blotting.
Immunocytochemistry and Confocal Microscopic Analysis. The subcellular lo-
calization of β-catenin protein in the hMSCs was examined by immunocy-
tochemistry as previously described (8). Culture slides were incubated with
mouse anti–β-catenin antibodies (Santa Cruz Biotechnology) at a dilution
of 1:500 in a solution containing 0.5% Triton X-100 and 10% normal goat
serum (NGS) for 2 h at 37 °C. After several washes in PBS, the culture slides
were incubated with rhodamine-conjugated anti-rabbit IgG-R (Santa Cruz
Biotechnology) at a dilution of 1:500 for 45 min at room temperature and
visualized using an Olympus IX70 microscope equipped with an Olympus
20× objective lens (numerical aperture 0.55) at 20 °C.
For confocal microscopic analysis, the cells were seeded on Ibidi eight-well
slides and incubated overnight with conditioned hMSC medium. The medium
contained secreted TIMP-1 to saturate potential TIMP-1 surface docking re-
ceptors on the hMSCs. The cells were fixed with methanol-free 4% formalin
and thenwashed and stainedwithmonoclonal anti-TIMP-1 (Chemicon) (1:500)
and anti-CD63 (Santa Cruz) (1:125) antibodies. Nuclei were fluorescently la-
beled with Hoechst 33342 (Thermo Scientific). All secondary antibodies were
purchased from Invitrogen. Confocal images were obtained using a Zeiss LSM
510 microscope equipped with a 40× oil immersion objective. Pinhole diam-
eters were adjusted to visualize 1.5-μm optical slices. To detect spots of
colocalization of both proteins, fluorescence intensity profiles were obtained
from representative images. Intensity peaks that were detected at both
emission wavelengths indicated areas of colocalization.
Statistical Analysis. Statistical significance was assessed by comparing mean
(±SD) values, using Student’s t tests for independent groups. One-way
analysis of variance followed by Dunnett’s test was used to compare mul-
tiple groups. Significance was assumed for P < 0.05. Statistical analysis was
conducted using Origin 8.0 software (OriginLab).
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